1. Home
  2. SBFG vs PMN Comparison

SBFG vs PMN Comparison

Compare SBFG & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

HOLD

Current Price

$26.88

Market Cap

164.8M

Sector

Finance

ML Signal

HOLD

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$15.21

Market Cap

136.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBFG
PMN
Founded
1983
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.8M
136.2M
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
SBFG
PMN
Price
$26.88
$15.21
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$42.67
AVG Volume (30 Days)
62.8K
55.9K
Earning Date
04-23-2026
05-13-2026
Dividend Yield
2.98%
N/A
EPS Growth
27.33
N/A
EPS
0.69
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$39.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.16
$0.29
52 Week High
$27.69
$27.40

Technical Indicators

Market Signals
Indicator
SBFG
PMN
Relative Strength Index (RSI) 67.71 66.97
Support Level $20.94 $9.87
Resistance Level N/A $19.85
Average True Range (ATR) 0.99 1.40
MACD 0.09 0.16
Stochastic Oscillator 85.11 73.88

Price Performance

Historical Comparison
SBFG
PMN

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: